MOUNTAIN VIEW, Calif., Jan. 17 /PRNewswire/ -- ChemoCentryx, Inc. today
announced the appointment of Edward E. Penhoet, Ph.D., to the company's
Board of Directors. Dr. Penhoet is recognized for his 25 years of
leadership and contributions in the public and private sectors of the life
sciences industry, including as co-founder and Chief Executive Officer of
Chiron Corporation (now Novartis).
Dr. Penhoet is currently the President of the Gordon and Betty Moore
Foundation, overseeing the philanthropic activities of the Foundation since
2004. Dr. Penhoet has also held the position of Director with Alta
Partners, a venture capital partnership investing in life science
companies, since 2000. From 1998 to 2002, he served as Dean of the School
of Public Health at the University of California, Berkeley. In 1981, Dr.
Penhoet co-founded Chiron Corporation and served as its Chief Executive
Officer until 1998. Prior to founding Chiron, he was a faculty member of
the Biochemistry Department of U.C. Berkeley. Dr. Penhoet also serves as
the Vice Chairman of the Independent Citizen's Oversight Committee of the
California Institute for Regenerative Medicine which was created by the
passage of Proposition 71, also known as the stem cell initiative.
A member of the Institute of Medicine of the National Academies of
Sciences and a member of the American Society of Biological Chemists, Dr.
Penhoet has co-authored more than 50 scientific articles and papers. In
addition to ChemoCentryx, he serves as a Director of Zymogenetics,
Scynexis, Metabolex and Renovis, Inc.
Dr. Penhoet earned his A.B. in biology from Stanford University, and
his Ph.D. in biochemistry from the University of Washington. He was a
post-doctoral fellow at the University of California, San Diego.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company
focused on discovering, developing and commercializing orally-administered
therapeutics that target the chemokine and chemoattractant systems in order
to treat autoimmune diseases, inflammatory disorders and cancer. The
chemokine system is a complex network of chemokine molecules, or ligands,
and receptors that regulates inflammation. Based on its proprietary drug
discovery and drug development platform, ChemoCentryx has internally
generated several clinical and preclinical-stage programs, each targeting
distinct chemokine and chemoattractant receptors with different small
molecule compounds. ChemoCentryx's lead compound, Traficet-EN(R), a
specific CCR9 antagonist, is currently in a multi-national clinical trial,
called PROTECT-1, for patients with moderate-to-severe Crohn's disease. For
more information, please refer to http://www.chemocentryx.com.
ChemoCentryx believes that certain statements in this release may
constitute "forward-looking statements" within the meaning of Section 21E
of the Securities Exchange Act of 1934 and Section 27A of the Securities
Act of 1933. These statements are based on current expectations and
assumptions regarding future events and business performance and involve
certain risks and uncertainties that could cause actual results to differ
materially. These statements are often, but not always, made through the
use of words or phrases such as believe, will, expect, anticipate,
estimate, intend, plan and would. Forward-looking statements are not
guarantees of performance. They involve known and unknown risks,
uncertainties and assumptions that may cause actual results, levels of
activity, performance or achievements to differ materially from any
results, levels of activity, performance or achievements expressed or
implied by any forward-looking statement. Some of the risks, uncertainties
and assumptions that could cause actual results to differ materially from
estimates or projections contained in the forward-looking statements
include, but are not limited to (i) that ChemoCentryx anticipates incurring
significant losses for the foreseeable future, (ii) dependence on the
success of Traficet-EN(TM); (iii) delays in obtaining or a failure to
obtain regulatory approval for product candidates, (iv) failure of any
approved product to achieve significant commercial acceptance in the
medical community or receive reimbursement by third-party payors, (v) the
timing, success and cost of preclinical research and clinical studies, (vi)
the timing, acceptability and review periods for regulatory filings, (vii)
the availability of corporate partners, (viii) uncertainties relating to
patent protection and intellectual property rights, (ix) the impact of
competitive products and technological changes, (x) competition from other
pharmaceutical or biotechnology companies, (xi) the availability of capital
and the cost of capital, (xii) other vagaries in the biotechnology industry
and (xiii) other risks. ChemoCentryx undertakes no obligation to update or
revise any forward-looking statements to conform the statement to actual
results or changes in the Company's expectations.
SOURCE ChemoCentryx, Inc.
 back to top
Related links:
http://www.chemocentryx.com
CONTACT:
Susan M. Kanaya, Senior Vice President,
Finance and Chief Financial Officer, or Markus J. Cappel, Ph.D.,
Chief Business Officer, +1-650-210-2900,
investor@chemocentryx.com; or Karen L. Bergman, +1-650-575-1509,
or Susan Pietropaolo, +1-845-638-6290, mobile, +1-201-923-2049,
both of BCC Partners, for ChemoCentryx, Inc.
|
